The ideal diet for us

Here’s the lowdown on the ideal diet – read further if you want to know.. From the (

Mediterranean diet and metabolic syndrome

MARCH 7, 2011 | Michael O’Riordan

Athens, Greece – A diet high in monounsaturated fatty acids, fruits, vegetables, whole-grain cereals, and low-fat dairy products, coupled with fish, poultry, nuts, legumes, and a low consumption of red meat—also known as the Mediterranean diet—is associated with a lower prevalence and slower progression of metabolic syndrome, according to the results of a new meta-analysis [1].

In addition, adhering to the Mediterranean diet had favorable effects on individual components of the metabolic syndrome, including waist circumference, HDL-cholesterol and triglyceride levels, blood pressure, and glucose metabolism, report investigators.

“These results are of considerable public-health importance, because this dietary pattern can be easily adopted by all population groups and various cultures and cost-effectively serve for the primary and secondary prevention of the metabolic syndrome and its individual components,” write Christina-Maria Kastorini (Harokopio University, Athens, Greece) and colleagues in the March 15, 2011 issue of the Journal of the American College of Cardiology.

The results are from a meta-analysis of 35 clinical trials, two prospective studies, and 13 cross-sectional studies and include data on more than 500 000 study participants. Among the clinical trials and prospective studies, adherence to the Mediterranean diet was “highly protective,” report investigators, with those subjects adhering to the diet having a 31% lower risk of developing metabolic syndrome.

Two of four cross-sectional studies that looked at the relation between metabolic syndrome and the Mediterranean diet found that adherence to the diet was associated with beneficial effects on metabolic syndrome, but when all studies were combined, the protective effect of the diet did not reach statistical significance.

Data from the clinical trials also showed positive effects of the diet on the individual components of the metabolic syndrome. Overall, adherence to the diet in the 35 clinical trials was associated with a 42-cm reduction in waist circumference, a 1.17-mg/dL increase in HDL cholesterol, a 6.14-mg/dL decrease in triglyceride levels, a 2.35-mm-Hg and 1.58-mm-Hg reduction in systolic and diastolic blood pressure, respectively, and a 3.89-mg/dL reduction in glucose levels.

“The results of the present meta-analysis add to the existing knowledge, because they indicate that adherence to the Mediterranean diet has a positive effect on human health through different ways,” conclude Kastorini and colleagues. “The Mediterranean diet has a beneficial effect on abdominal obesity, lipid levels, glucose metabolism, and blood-pressure levels, all the components of the metabolic syndrome, which are also risk factors for the development of cardiovascular disease, insulin resistance, and diabetes.”

Aspirin reduces cancer deaths

This interesting article from the Lancet shows that aspirin has additional benefits to its antiplatelet effects.

From the New York Times:

December 6, 2010

Aspirin Helps in Reducing Cancer Deaths, a Study Finds

Many Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.

As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.
Continue reading

Antibiotic used on drug-eluting stents may lead to advances in heart disease and cancer treatment

RapamycinScienceDaily (Apr. 14, 2010) — Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

The study is published in the April 16th issue of the Journal of Biological Chemistry.

The antibiotic, rapamycin, is used on drug-eluting stents implanted during angioplasty because it is effective in preventing restenosis (re-narrowing or reclosure) of arteries. However, rapamycin can also prevent tissue from growing over and covering the metal stents, a critical part of the artery’s healing after angioplasty. Without this protective covering, blood clots can develop many months later, called late stent thrombosis. These clots can lead to a heart attack.

Continue reading